Project Grant R01HL188168
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $818K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Northwestern University $696,259 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop flexible electronics and optogenetics approaches for real-time arrhythmic profiling of engineered heart tissues. The project runs through April 30, 2031, with work performed in Chicago, Illinois. The award funds development of non-invasive arrhythmia assessment methods for human induced pluripotent stem cell–derived...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $1,368,536 on August 13, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop fair and efficient allocation algorithms for continuous distribution of donor hearts in transplantation. The project addresses critical gaps in the current therapy-based heart allocation system, which the recipient has demonstrated to be vulnerable to manipulation, sensitive to treatment practice changes, and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Loyola University of Chicago Health Sciences Campus $1.25 million on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on specific regulation of cardiac atrial contractility in cardiomyopathy. The research establishes the physiological significance and mechanisms by which myosin binding protein H-like (MYBP-HL), an atrial-specific protein, regulates cardiac...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Indiana University $516,592 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects using random field methods. The research leverages existing biospecimens and data from the National Birth Defect Prevention Studies, the Pediatric Cardiac Genomics Consortium, and the Trans-Omics for...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $124,688 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode the gene regulatory network of mammalian cardiac maturation. The award funds a K99/R00 research project investigating the molecular mechanisms driving postnatal cardiac development. During the K99 phase, the recipient will characterize epigenomic changes in the mouse heart during...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, operating as Lawrence Berkeley National Laboratory, $2,057,231 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map and decode the enhancer landscape of human heart development. The award funds a research project that creates a single-cell enhancer atlas of the developing human heart by integrating genome-wide single-cell multiome data from critical...
- The National Heart, Lung, and Blood Institute awarded The Broad Institute, Inc. $173,825 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct functional genomics research investigating gene regulatory networks in cardiac fibrosis. The award funds research to identify and characterize the transcriptional regulators that promote and maintain the activated cardiac fibroblast cell state in heart failure patients. Cardiac fibrosis—the excessive deposition of...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute awarded New York University $1,692,126 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA upregulated in atherosclerotic cardiovascular disease. The research will map CHROMR-protein interfaces and design steric-blocking oligonucleotides to selectively disrupt the CHROMR-IRF2BP2 interaction, decoupling its pro-inflammatory...